Another addition to the list of BET inhibitor trials. Orion Corporation/Orion Pharma in collaboration with Aurigene have a pan-BET inhibitor ODM-207. Appears that they have a single clinical trial ongoing that started last December. It appears to just be a single agent trial and not a combo therapy trial at this point.

Although that clinical trial is not focusing on prostate or breast cancer, a 2017 poster suggests that this is a focus of their pre-clinical research. In fact, these guys have been very active presenting at a variety of oncology conferences in 2017. Also, if you look at Orion's recent publication/poster list, you can see that they not only have shown pre-clinical efficacy of ODM-207 in prostate and breast cancer, but also immuno-oncology. Best to keep an eye on the progress and developments of this company and molecule.

Clinical Trial: ODM-207 in Patients With Advance Solid Tumours (BETIDES)

2017 Poster: Targeting cancer with a novel BET bromodomain inhibitor

What caught my eye in the poster is that ODM-207 "inhibits proliferation and downregulates Myc levels in prostate cancer cells that have acquired resistance to BET-inhibitor OTX015." That is extremely interesting and suggests that development of resistance to BET-inhibitor A does not preclude the potential efficacy of BET-inhibitor B.

P.S. For those who didn't see my original message in this thread, it is a fairly (but obviously incomplete) list of ongoing BET inhibitor trials mainly in the oncology area (except for Resverlogix).

P.P.S. I sent the list of questions (including those ?'s offered by others) to Resverlogix and Zenith. Clayton already responded (to the Zenith email) that he would send on to senior management.